FDA Blows Past Deadline on Hemp Cannabinoid Lists, Container Rules

August 24, 2026

Photo by Elsa Olofsson via Unsplash.

Federal deadlines have a way of quietly slipping past without much notice, but this one comes with a hard expiration date attached to an entire industry. The FDA was supposed to publish specific lists of hemp cannabinoids -- and finalize guidance on what counts as a product container -- under a law President Trump signed in November 2025. That deadline came and went in February 2026, and as of now, the agency still hasn't produced either document.

The Congressional Research Service, Congress's own nonpartisan research arm, has now flagged the failure in an official report designated IF13136, noting that the FDA is more than six months behind schedule on a mandate it was given zero ambiguity about. That's not a think tank or an advocacy group making the accusation -- it's the research service that answers directly to lawmakers.

The stakes here aren't abstract. Without those cannabinoid lists, hemp retailers, manufacturers, and formulators have no way of knowing which of their products will remain legal and which will become federally illegal the moment a new statutory definition of hemp kicks in on November 12, 2026. What follows is a look at exactly what the law demanded, how badly the FDA has missed the mark, what it's costing businesses in the meantime, and where Congress currently stands on trying to buy the industry more time.

What the Law Actually Requires

Photo by Mikhail Nilov via Pexels.

The mandate traces back to P.L. 119-37, the appropriations and continuing resolution package Trump signed into law in November 2025. Tucked inside that broader spending bill was language directing the FDA to take concrete regulatory action on hemp-derived cannabinoids within a tight window -- 90 days from enactment, putting the hard deadline at February 10, 2026.

Specifically, the law required the FDA to consult with other federal agencies and then publish three distinct lists. The first is meant to be comprehensive: every cannabinoid known to the FDA that's capable of being naturally produced in a cannabis plant, regardless of how it's typically synthesized or sold commercially. The second narrows in on THC-class cannabinoids specifically, the compounds most directly tied to intoxicating effects and the ones most likely to trigger new restrictions. The third list is meant to catch everything else -- cannabinoids the agency considers to have effects similar to THC even if they aren't chemically classified alongside it.

On top of the three lists, the FDA was also tasked with further defining the term container, which the bill itself had already sketched out in broad strokes as the innermost packaging in direct contact with a hemp-derived product sold at retail -- things like jars, bottles, bags, boxes, packets, cans, cartons, and vape cartridges. Lawmakers wanted the agency to sharpen that definition so manufacturers know exactly what packaging and labeling rules apply to their specific product format. Ninety days was the window Congress gave the FDA to get all of this done. That window closed months ago.

Six Months Late and Counting

Two Congressional Research Service products, IF13136 and IN12620, both available on Congress.gov, lay out the situation plainly: as of their most recent reporting, the FDA has not released the cannabinoid lists or the container guidance it was ordered to produce. These aren't leaked internal documents or anonymous tips -- they're formal research briefs prepared for members of Congress and their staff to reference.

A Haze Connect analysis published within the past week puts a sharper number on the delay, calculating that the agency is now more than six months past its February 10 deadline with no published lists, no Federal Register notice, and no public timeline for when either might appear.

This isn't for lack of prior assurance. Health and Human Services, which oversees the FDA, previously told Marijuana Moment that it intended to publish the cannabinoid lists on schedule in the Federal Register. That commitment simply hasn't materialized. When pressed again for an update on where things stand, agency officials did not respond with any clarification or revised timeline.

Hemp industry advocates who've been tracking FDA's cannabinoid policy for years say this fits a familiar pattern rather than representing an isolated lapse. The agency has a documented history of missing or simply declining to act on congressional deadlines related to CBD and other hemp compounds, going back to earlier directives that similarly asked FDA to clarify regulatory pathways and never fully delivered. For an industry that's been waiting on regulatory clarity since the 2018 Farm Bill first legalized hemp, this latest silence reads less like a fluke and more like business as usual.

Why the Silence Is Costing the Hemp Industry

Photo by Saul Rivera via Pexels.

The practical consequence of FDA's inaction is that nobody in the hemp supply chain -- growers, extractors, brand owners, retailers -- can say with confidence which cannabinoids will be swept into the new THC-class definition and which will remain on the legal side of the line. That distinction matters enormously, because a new statutory definition of hemp is set to take effect on November 12, 2026, and it's written broadly enough to effectively ban a huge swath of products that became legal under the 2018 Farm Bill during Trump's first term.

Industry estimates circulating among trade groups suggest the redefinition, as currently written, could eliminate somewhere around 95% of the existing hemp cannabinoid market. That includes delta-8 products, delta-9 THC beverages, and the broader category of intoxicating hemp derivatives that have built a multibillion-dollar retail footprint over the past several years, sold everywhere from gas stations to dedicated hemp shops to mainstream grocery chains in states that allow it.

Without the FDA's lists, businesses are staring down what amounts to a compliance cliff with no map. Reformulating a product line, sourcing alternative cannabinoids, or redesigning packaging isn't something that happens overnight -- it takes months of lead time, testing, and coordination with manufacturers and retailers. Container guidance factors into this directly too, since packaging decisions have to be locked in well ahead of any rule change, and companies can't finalize labeling or container specs when the underlying definitions they're supposed to comply with haven't been published. The closer November 12, 2026 gets without answers, the less time there is to do any of this responsibly.

Industry and Congress React

Jonathan Miller, general counsel of the U.S. Hemp Roundtable, has been one of the more vocal voices connecting FDA's missed deadline to the industry's broader legislative predicament. Miller has pointed out that the agency's slowness -- or outright disregard -- toward congressional deadlines on hemp issues isn't new, and he argues this latest delay makes it that much more urgent for Congress to step in and extend the compliance timeline itself. His reasoning is straightforward: there simply isn't enough runway left to build a coherent, workable regulatory regime before November if the agency responsible for the underlying definitions hasn't even published them yet.

Several bills are currently pending that would address this in different ways. The HEMP Act, introduced by Reps. Morgan Griffith and Marc Veasey, takes one approach to reworking the hemp definition. The Hemp Planting Predictability Act, backed by Sens. Amy Klobuchar, Rand Paul, Jeff Merkley, and James Comer, would push the effective ban date out to 2028, giving the industry and regulators substantially more time. The Lawful Hemp Protection Act, from Reps. Angie Craig and Andy Barr, offers yet another legislative fix aimed at the same underlying problem.

The Senate did take action, voting on August 8, 2026 to delay the ban, but the House hasn't agreed to matching language, and nothing has been signed into law. That means November 12, 2026 remains the operative deadline under current statute, regardless of what any single chamber has passed. Adding another layer to the debate, the White House issued a statement earlier this year backing congressional action to preserve the legality of full-spectrum CBD products, signaling at least some appetite within the administration for a legislative patch even as its own health agency stays quiet on the regulatory groundwork.

What's happening here isn't just an agency running behind on paperwork. Every month the FDA stays silent on these lists is a month Congress doesn't have to negotiate, draft, and pass a fix before the November 12, 2026 deadline arrives. The lists and container guidance were supposed to be the foundation lawmakers could build an extension or a permanent solution on top of -- instead, Congress is being asked to legislate blind, without knowing exactly which cannabinoids and products are even on the chopping block.

Hemp businesses and consumers in every state have reason to watch this closely, because whatever definition eventually takes hold at the federal level will interact with the patchwork of state hemp laws already on the books, some far more permissive than others and some already moving to restrict intoxicating hemp products on their own timeline. Rules are shifting on multiple fronts at once, so anyone selling, buying, or formulating hemp products right now should confirm current requirements with their state regulators and legal counsel rather than assuming today's rules will hold through next fall.

Barring a late push from either chamber or a sudden burst of activity out of FDA, the November 12, 2026 cutoff is going to arrive as the default outcome of inaction, not as the product of any deliberate policy decision. That's an uncomfortable way for an industry this size to find out where it stands.